NCT04649632

Brief Summary

Determining the mean/median time between botulinum toxin-A injection within the treatment of patients with spasticity after stroke in relation to the botulinum toxin dose from a healthcare insurance database in the Netherlands.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
451

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 29, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 18, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 18, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 12, 2020

Completed
20 days until next milestone

First Posted

Study publicly available on registry

December 2, 2020

Completed
Last Updated

December 2, 2020

Status Verified

November 1, 2020

Enrollment Period

5 months

First QC Date

November 12, 2020

Last Update Submit

November 25, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Mean time to next injection per brand

    From baseline up to end of data collection (January 2012 up to December 2016)

  • Median time to next injection per brand

    From baseline up to end of data collection (January 2012 up to December 2016)

  • Dosing of botulinum toxin-A in daily practice in relation to time to next injection

    From baseline up to end of data collection (January 2012 up to December 2016)

Secondary Outcomes (3)

  • Average cost per year per brand per patient

    From baseline up to end of data collection (January 2012 up to December 2016)

  • Exploring factors like age, gender, time since diagnosis stroke that influence dosing and time between botulinum toxin-A treatments

    From baseline up to end of data collection (January 2012 up to December 2016)

  • Time interval between 2 injections of the same brand

    From baseline up to end of data collection (January 2012 up to December 2016)

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients selected from the database claimed within the code 313 will be included in the descriptive analyses.

You may qualify if:

  • A patient will be included if he has a diagnosis stroke within the rehabilitation setting and has received at least two injections of botulinum toxin-A: Dysport or Botox

You may not qualify if:

  • A patient will be excluded if he has been only treated with Xeomin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ipsen Facility

Hoofddorp, 2132LS, Netherlands

Location

Study Officials

  • Ipsen Medical Director

    Ipsen

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2020

First Posted

December 2, 2020

Study Start

April 29, 2020

Primary Completion

September 18, 2020

Study Completion

September 18, 2020

Last Updated

December 2, 2020

Record last verified: 2020-11

Locations